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ABSTRACT
Treating patients with progressive 
supranuclear palsy (PSP) is both effective 
and rewarding. This review aims to share 
our experience in the proactive management 
of PSP, considering the patient, the family 
and the medical context in which the illness 
unfolds. There are many opportunities 
to assist your patients, ameliorate their 
symptoms, reduce their risks and harm, 
and guide them through the complex 
medical, social and legal minefield that 
characterises life with chronic neurological 
illness. We summarise the challenges of early 
diagnosis, consider PSP mimics and the role 
of investigations in excluding these, and 
discuss the available pharmacological and 
non- pharmacological treatment strategies 
to tackle the common and challenging 
symptoms of PSP. The best treatment 
will be patient centred and as part of a 
multidisciplinary team.
INTRODUCTION
Progressive supranuclear palsy (PSP) is 
not yet curable, but many aspects are 
certainly treatable. Indeed, the support 
and management of people with PSP 
can be both effective and rewarding. 
This article shares our experience in 
its proactive management, considering 
the patient, the family and the medical 
context in which the illness unfolds. 
Effective management starts with 
achieving an early, accurate diagnosis. 
We review new concepts in the diag-
nosis of PSP that have emerged over 
the last 10 years. We then consider 
the differential diagnosis and the role 
of investigations. We go on to review 
pharmacological treatment options 
and non- pharmacological aspects to 
effective holistic care, support and 
management.
Diagnosis of PSP
By the time of diagnosis, patients with 
PSP are typically 3 years from their first 
symptom.1 That is halfway through 
the illness. The lateness of diagnosis 
is multifactorial with delays seeking 
general practitioner advice, failure to 
recognise the significance of early symp-
toms and misdiagnosis as depression 
and/or Parkinson’s disease. Part of the 
problem is the terminology of ‘atypical 
Parkinsonism’. There is nothing ‘atyp-
ical’ about PSP: it is typical of PSP, and 
readily distinguished from Parkinson’s 
disease. For example, the limb signs in 
PSP are symmetrical, without tremor 
and rigidity is marked in the trunk and 
neck, and minimal in the periphery—
the opposite of Parkinson’s disease on 
all counts.
The diagnosis of PSP is usually not 
difficult with a few easy tips, set out 
in table 1. Many of these apply even 
soon after symptom onset. Is there 
a tendency to fall over easily, in the 
first year of symptoms? Yes for PSP, no 
for Parkinson’s disease. Are the eyes 
‘staring’, with an odd, fixed smile or 
grimace? Yes for PSP, no for Parkinson’s 
disease. Do they walk with head up and 
forward (poetically called sniffing the 
morning breeze)? These features take 
seconds to take in as the patient walks 
to the consulting room.
Once in the consulting room, further 
differences are obvious. Typical PSP 
speech is not the quiet, hypophonia 
of Parkinson’s disease, but a more 
chaotic dysarthrophonia: distorted, 
slow and effortful, sometimes inap-
propriately loud then indistinct, often 
nasal in quality or low pitched with a 
‘gravelly drawl’. Speech may be mixed 
in with laughter, perhaps inappropri-
ately. There is much less spontaneous 
speech—known as adynamic aphasia.
There may be changes in personality. 
In the history, families may have noticed 
the person with PSP becoming apathetic 
(losing ‘get up and go’, zest, motivation, 
or interest); or becoming self- centred and 
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stubborn. These reflect the common cognitive impair-
ments of PSP, and its relationship to frontotemporal 
dementias.2 Despite a history of apathy, patients may 
also be impulsive, leaping up from their chair as you 
approach, or in anticipation of your request to stand, 
even if balance is poor.
Look at their eyes. You may notice a blank, staring 
appearance, with few spontaneous blinks, a furrowed 
brow and raised eyebrows. Look closely for small 
square wave jerks in neutral gaze. These are small 
(2°–4°), horizontal, brief (less than a second before 
returning to target), and frequent (every few seconds). 
Early in the course of PSP, there can be a full range of 
eye movements, but a key feature for the diagnosis is 
the presence of either (1) restricted vertical saccadic 
movements in a supranuclear pattern or (2) slow 
saccades (tip: compare vertical to horizontal saccades). 
A valuable sign that is not in the formal diagnostic 
criteria, but which can be seen before restriction and 
slowing, is a curvilinear path on downward saccades 
(‘round- the- houses’ sign, see figure 1). Slowing and 
‘round- the- houses’ are best seen with saccadic move-
ments on command to a target. The supranuclear gaze 
palsy from which PSP is named causes restriction of 
voluntary eye movements in the vertical plane (up, 
down or both). The patient overcomes the restriction 
(at least in part) by reflexive eye movements when you, 
the clinician, tilt the patient’s head with them fixating 
on a target (Tip: if the neck becomes too rigid to tilt 
the head, try holding gently with both hands either 
side, and wobbling it a few degrees left and right first, 
before a downward tilt). Other dementia syndromes 
can cause a ‘pseudo- gaze palsy’ due to ocular apraxia 
(eg, posterior cortical atrophy, Alzheimer’s disease 
and corticobasal degeneration, Huntington’s disease), 
in which a patient initially appears unable to look up 
or down to a target, while reflexive movements are 
preserved with head tilting. However, with repeated 
attempts, it is possible in these conditions to elicit a 
fast and full saccade to the vertical target.
Are they dopa- responsive or not dopa- responsive? 
One of the criteria for the diagnosis of PSP is that it 
is poorly responsive to levodopa. This is poor with 
respect to the level of response in Parkinson’s disease. 
But ~30% of patients report some benefit to levodopa 
or dopamine agonists. The effect is mild, and they may 
describe vague benefits in mobility, speech, ‘energy’ and 
other symptoms. Only conclude non- responsiveness if 
a high dose has been given (750–1000 mg daily). Note 
that PSP does not cause dyskinesia, or dopa- induced 
dyskinesia (unlike Parkinson’s disease). The dose can 
be rapidly increased over 6–8 weeks and decreased 
rapidly if not effective.
So, PSP is not Parkinson’s disease! It is usually not 
difficult to diagnose the classical presentation, known 
commonly as Richardson’s syndrome. Table 2 gives 
a list of distinguishing features, but just ask yourself, 
‘does this person actually look like the other people 
with Parkinson’s disease that I have seen?’ The answer, 
with PSP, will be ‘No’.
New variants of PSP
When Steele et al,3 first described PSP, seven of their nine 
cases had dementia or severe cognitive and behavioural 
change. Despite this, the illness became known as a 
movement disorder, allied to Parkinson’s disease—a 
problem exacerbated by terms like ‘Parkinson- plus’ 
and ‘atypical parkinsonism’. However, the importance 
of cognitive and behavioural change has increased 
with recent recognition that cognitive change is almost 
Table 1 Symptoms and signs of PSP
Symptoms Signs
Cognitive change (apathy, 
impulsivity)
Akinetic rigidity—neck and axial rigidity 
>limbs ‘sniffing morning breeze sign’
Impaired balance Slow saccades and ‘round the houses’ 
vertical saccades
Early falls (with increased 
fracture risk)
Vertical supranuclear gaze palsy
Blurry or double vision Frontalis overactivity, reduced blink, staring 
expression
Sleep difficulties Tendency to lose balance spontaneously or 
on the ‘pull test’
Dysphagia (especially liquids) Uncontrolled decent into a chair
Drooling, sialorrhoea Dystonia, cervical, axial >limbs
Urinary urgency or 
incontinence
Apraxia (CBS overlap)
Constipation Emotional lability (pseudobulbar affect)
Depression or anxiety Reduced verbal fluency
Hyperphagia and change in 
food preferences
Dysarthrophonia
Weight loss (with possible 
malnutrition)
  
CBS, corticobasal syndrome; PSP, progressive supranuclear palsy.
Figure 1 Left: ‘Round- the- houses’ sign, illustrated for a 
downward saccade. Note the lateral curvature of downward 
path of eye movement (yellow arrows). The velocity may also 
be slow. Right: the face gives many clues to the diagnosis: 
as shown by this gentleman, there may be retrocollis, raised 
eyebrows and frontalis overactivity. People with PSP may have 
a rather fixed smile, with lips drawn back rather than up. The 
eyebrows sometimes appear knitted together (not shown). 
For video clips of other signs of PSP, refer to the ‘quick links to 
further information section’. PSP, progressive supranuclear palsy.











3Rowe JB, et al. Pract Neurol 2021;0:1–9. doi:10.1136/practneurol-2020-002794
Review
universal in PSP, and that up to half of patients do not 
present with the classical Richardson’s syndrome.
The new 2017 diagnostic criteria for PSP4 recognise 
these ‘variant’ presentations. Most eventually evolve 
to look like classical Richardson’s syndrome, but 
knowing the variants will allow you to make an earlier 
diagnosis with confidence. They include:
1. PSP- Speech and Language (SL) with a non- fluent aphasia, 
preceding typical changes of PSP.
2. PSP- Frontal (F): prominent apathy, impulsivity and inap-
propriate behaviour.
3. PSP- corticobasal syndrome (CBS) with CBS- like signs of 
asymmetric dystonia, apraxia, cortical sensory loss, my-
oclonus or alien- limb.
4. PSP- Progressive gait freezing (PGF), with sudden motor 
block, hesitation or initiation failure when walking. PSP- 
PGF can occur many years before oculomotor signs and 
is highly predictive of PSP. Akinesia is profound, while 
cognition remains essentially intact.
5. PSP- Parkinsonism in which patients begin with asym-
metry in limb features, tremor, and even levodopa re-
sponsivity, later developing more typical PSP features 
(Richardson’s syndrome).
The new criteria also introduce formal levels 
of diagnostic certainty, from definite (pathology 
confirmation); probable, possible and ‘suggestive 
of ’ PSP. The latter class of ‘suggestive of ’ PSP 
refers to people with limited signs of PSP, failing 
to meet former standard criteria, but nonetheless 
with a significant prognostic value for PSP. In this 
case, be honest about your suspicion of PSP, initiate 
symptomatic treatment and follow- up.
These new categories of PSP may seem complex. 
But, the details matter less than recognition that 
PSP presents with a wide range of changes in cogni-
tion, language and behaviour.
Differential diagnosis and the [limited] role of 
investigations
PSP is essentially a clinical diagnosis, and when 
made by a neurologist has very high clinicopath-
ological correlations. There are differential diag-
noses (table 3), with clinical clues to guide you. 
Investigations are mainly used to rule out mimics 
and to look for uncommon reversible alternatives. 
We present them in a didactic manner, but this is 
no substitute for clinical judgement of a given case.
Blood tests may occasionally identify unlikely 
mimics (low thyroid stimulating hormone, positive 
syphilis serology), but are more useful to consider 
the consequences of disability and guide falls risk- 
reduction (full blood count, clotting, bone profile, 
vitamin D, B12, folate), or to manage latent comor-
bidities that complicate the course of PSP (glycated 
haemoglobin HbA1c, urea, creatinine and elec-
trolytes). More exotic tests (HIV, copper, caeru-
loplasmin, ferritin, antinuclear antibody, genetics, 
white cell enzymes) may be indicated in young 
onset cases (<50 years) or atypical phenotypes 






Even in loose limbs
Mild to moderate
Tremor No Yes
Falls Early, spontaneous Late, with 
freezing
Eyes Vertical paresis Normal*
Voice Dysarthrophonia, 
distorted, poor volume 
control
Hypophonia, quiet




executive changes or 
later dementia
Levodopa Poor response Very good response








Bold text highlights the simplest quick- six to have in mind.
* Subtle oculomotor abnormalities occur
PSP, progressive supranuclear palsy.
Table 3 Differential diagnosis for progressive supranuclear palsy other 
than Parkinson's disease.
 
Disease Clues to diagnosis
CBS Early asymmetric akinesia, apraxia, dystonia, 
myoclonus
MSA Predominant autonomic features, cerebellar 
signs
FTD Predominant behaviour features, marked 
atrophy
NPH Supportive imaging findings
Vascular disease Supportive imaging findings, vascular risk 
factors
Structural lesion Supportive imaging findings
Rare genetic mimics Young age of symptom onset, relevant family 
history
DLB Hallucinations and fluctuations common
AD Disproportionate memory impairment, 
hippocampal atrophy on MRI, suggestive CSF 
biomarkers
These differential diagnoses may cause abnormal eye signs, but lack the 
distinctive selective vertical gaze palsy and slowing of PSP and the other 
characteristic clinical face and limb signs of PSP.
AD, Alzheimer's disease ; CBS, corticobasal syndrome; DLB, Dementia 
with Lewy bodies ; FTD, Frontotemporal dementia ; MSA, Multiple 
System Atrophy ; NPH, Normal Pressure Hydrocephalus ; PSP, progressive 
supranuclear palsy.
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(movement disorders other than those above or 
with white matter pathology on MR brain scan).
PSP is a sporadic disease, and routine genetic 
testing is not indicated. However, if there are first 
degree relatives with a neurodegenerative condition 
under 65 years, or multiple relatives with neurode-
generative disorders, then consider genetics testing 
with C9orf72 and a next- generation sequencing 
dementia panel. Most relevant disorders in the 
family are PSP, Parkinson’s disease (try to get an 
account of the relative’s symptoms), frontotem-
poral dementia, progressive aphasia, motor neuron 
disease. Disorders that broadly resemble PSP can 
arise from mutations in C9orf72 (overlapping with 
frontotemporal dementia, motor neuron disease, 
aphasia, ataxia), microtubule associated protein 
tau (overlapping frontotemporal dementia, CBS), 
progranulin (GRN, overlapping frontotemporal 
dementia, aphasia), Park9 (Kufor- Rakeb syndrome) 
and CSF- 1R (hereditary leukoencephalopathy 
with axonal spheroids) among others. Niemann- 
Pick type C is often considered as a differential 
diagnosis, although the gaze palsy is horizontal or 
global, not selectively vertical.
MR scan of brain is the most useful diagnostic 
tool regarding PSP, not so much for the menag-
erie of positive signs (hummingbird sign, Mickey 
Mouse sign, figure 2A), but for its ability to exclude 
alternative diagnoses such as extensive small vessel 
disease, leukodystrophy, normal pressure hydro-
cephalus and frontal mass lesions (figure 2B).5
A DaTSCAN is rarely indicated. It will be abnormal 
in PSP (figure 2A), but it will also be abnormal in 
Parkinson’s disease, multiple system atrophy, and 
usually with corticobasal degeneration and frontotem-
poral dementia with parkinsonism. As such, the DAT 
scan is not helpful for differential diagnosis. It is rare 
that drug- induced parkinsonism or essential tremor 
are serious differentials for PSP. DaTSCANs add little 
to MR brain scan in differentiation of degenerative 
parkinsonism from vascular disease or normal pres-
sure hydrocephalus (although in the latter two it is 
usually normal). One area when a DaTSCAN can help 
is in distinguishing PSP from primary lateral sclerosis 
Figure 2 MRI and DaTscan features in PSP (A) and examples of MRI features of alternative diagnoses for PSP- like presentations (B), 
with arrows highlighling the salient feature or anomaly. MSA, multiple system atrophy; PSP, progressive supranuclear palsy.
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variant of motor neuron disease, which can cause 
akinesia (although without decrement), oculomotor 
slowing (including horizontal) and dysarthria. Fluo-
rodeoxyglucose positron emission tomography (FDG- 
PET) and ‘tau- PET’ are abnormal in PSP but are still 
primarily research tools.
Drug treatment of PSP
PSP cannot yet be cured, but treatment can be helpful. 
Each patient is different, and so the selection, timing 
and doses of the following drugs will vary from 
person to person. Except for dopaminergic therapy, 
the mantra should be ‘start low and go slow’, as PSP 
increases sensitivity to side effects, which can have 
severe consequences in a fragile medical condition or 
precarious social situation.
Symptom reduction
For many cognitive and behavioural symptoms, 
support, tolerance and environmental measures are 
more effective—and safer—than medication. Expe-
rience (anecdote) and cohort studies dominate the 
evidence base, over randomised, controlled clinical 
trials. So, focus on medications that aim to reduce 
those symptoms that trouble the patient, or place them 
at risk. The following sections are a guide, not a substi-
tute for clinical judgement. Ask the patient which of all 
the problems caused by PSP actually bothers them—
the answers may surprise you! PSP robs people of so 
many abilities and aspirations, but professionals often 
unwittingly remove the patients’ autonomy. Patient- 
centred treatment is more satisfying, more likely to 
succeed and better for risk- benefit decisions.
Motor symptoms: We recommend a trial of 
levodopa in all patients with significant akinetic 
rigidity, but usually not in people with PSP- F or PSP- 
SL. The range of options is the same as in Parkinson’s 
disease, but prescribing practice differs in PSP because 
of (1) the need for early clarity over responsiveness; 
(2) the faster rate of progression of PSP and (3) the 
much lower rates of common side effects of levodopa 
in PSP for example, less likely to cause nausea, hypo-
tension and dyskinesia (reflecting different striatal and 
autonomic pathology). We recommend 62.5 mg three 
times a day, doubling after 2 weeks and again after 2 
weeks, reaching 250 mg three times a day by 1 month, 
with further increases to 1000 mg/day if tolerated. 
This is much faster than one would escalate in Parkin-
son’s disease. We assess response by the patient- based 
and carer- based global impression of change by 2–3 
months. If it is not noticeably of benefit, then with-
draw over 4–6 weeks. Dopamine agonists are a reason-
able alternative to levodopa. They may be of particular 
value in PSP- PGF, using high doses (eg, increasing roti-
gotine stepwise to 16 mg/day).
Amantadine can be helpful, with patients reporting 
reduced axial rigidity, improved mobility, more 
‘energy’ and less fatigue, or clearer speech. Younger 
patients, aged under 60, are more likely to report 
benefits, while older patients, aged over 75, are 
more likely to experience significant side effects, for 
example, hallucinations and oedema. Start low (100 
mg at breakfast) and increase by 100 mg at two weekly 
intervals aiming for 300–400 mg total dose. Ensure 
that the second dose is not after lunchtime, as it may 
cause insomnia.
PSP- PGF may respond to cholinesterase inhibitors, 
reflecting the cholinergic nature of pedunculopontine 
gait- rhythm generators. With the generally favourable 
safety profile of these drugs, it is worth considering a 
trial period of donepezil (starting 5 mg, rising steadily 
to 20 mg once daily).
Myoclonus is rare in PSP but can occur in PSP- CBS. 
It rarely troubles the patient, even if obvious to others. 
It often responds low dose clonazepam (0.25–0.5 mg, 
once a day to two times a day), levetiracetam or lamo-
trigine, but avoid valproate in view of its potential to 
exacerbate parkinsonism.
Dystonia can be severe, and painful, with cervical 
dystonia affecting swallowing and social interaction. 
Topical non- steroidal anti- inflammatory drugs are 
a good first line treatment, particularly for shoulder 
dystonia. Amantadine may help but is unlikely to be 
sufficient on its own. Cholinergic approaches are not 
advised, because of their deleterious effect on cogni-
tion, balance and falls risk. Botulinum toxin is most 
effective, especially if combined with physiotherapy.
For bladder symptoms (eg, urgency and inconti-
nence), we recommend excluding other causes (eg, 
prostate enlargement, diuretics, caffeine) and using 
mirabegron. This has an advantageous side- effect 
profile over anticholinergic alternatives, although 
monitor for hypertension.
Psychiatric features of PSP: Given the degree of 
disability, depression is surprisingly uncommon in 
PSP. Akinesia, apathy and pseudobulbar affect (below) 
may be confused with depression. Patients can score 
highly on depression rating scales (from changes in 
sleep, energy, motivation, libido, etc), but the core 
symptom of low mood is rarely severe or persistent. 
A minority of patients have significant and perva-
sive depression and anxiety. We avoid tricyclics (eg, 
amitriptyline) because of the anticholinergic effects. 
Selective serotonin reuptake inhibitors (SSRIs), espe-
cially citalopram and sertraline, are well tolerated and 
effective, with potential additional benefits for impul-
siveness and pseudobulbar affect. Mirtazapine can be 
particularly useful if night- time sedation or increased 
appetite is desirable. Note that 15 mg mirtazapine is 
paradoxically more sedating and less antidepressant 
than 30 mg. Venlafaxine (a noradrenaline/serotonin 
reuptake inhibitor SNRI/SSRI) may help where there 
is accompanying anxiety.
People with PSP may suddenly cry intensely, 
appearing very distressed and tearful. This pseudob-
ulbar affect is upsetting to witness but does not always 











6 Rowe JB, et al. Pract Neurol 2021;0:1–9. doi:10.1136/practneurol-2020-002794
Review
reflect a patient’s inner distress. If asked, between the 
tears, they may deny feeling upset, or be aware of a 
surge of emotionality. The emotional lability can be 
laughter but is more often crying. If it is frequent, or 
distressing, then consider treatment; low dose citalo-
pram (10–20 mg) is usually very effective.
Sleep disturbance is common in PSP, but often not 
volunteered. Simple measures may be sufficient: stop-
ping diuretics; treating prostatic hypertrophy; recom-
mending both increased daytime activity and exercise 
and a limit on daytime naps to 30 min or less; reviewing 
and treating of depression and anxiety; and ensuring 
that drugs like amantadine that can cause insomnia 
are reviewed and taken earlier in the day. If this is 
not sufficient, then primary insomnia may respond 
to ‘Z- drugs’ like zolpidem, melatonin or short- term 
benzodiazepines, balancing the risks of sedation and 
falls against lack of sleep.
Keening, wailing, and perpetual ‘stammer’: Some 
patients utter repetitive, loud vocalisations for minutes 
or hours on end. This is exhausting to be near, and 
may be the last straw for carers at home, and may even 
prevent care- home placement. It resembles an extreme 
stammer, but with a quality that might suggest distress. 
It helps to explain to carers that it rarely indicates 
distress, and that it is part of the illness. If worse at 
night, then sedation as above may help.
Drooling and sialorrhoea: Drooling in PSP results 
from not swallowing saliva, rather than overproduc-
tion. It may be exacerbated by anterocollis: reposi-
tioning may be all that is required. We advise against 
hyoscine patches because of the harmful anticho-
linergic effects. A better alternative with negligible 
systemic side effects is oral atropine drops, 2–3 sublin-
gual drops, 2–3 times per day. The number of drops 
and frequency can be readily titrated, particularly if 
saliva becomes too thick. Alternatives are: salivary 
gland botulinum toxin, which is a less reversible/
titratable option; and oral glycopyrronium, although 
we are not convinced of its value in PSP given that it 
primarily aids chest secretions and may have systemic 
side effects.
Involuntary eye closure is common in PSP. It can be 
mild and irritating or severe with functional blindness. 
It may be caused blepharospasm (especially pretarsal 
blepharospasm) or apraxia of lid opening—the 
inability to open the eyes voluntarily despite normal 
peripheral levator function. It may respond well to 
botulinum toxin injections. Eyelid opening apraxia 
(not blepharospasm) is a diagnostic criterion for PSP 
but is uncommon in the early stages.
Reducing risk
Alongside the reduction of symptoms, be proactive 
to reduce the future risks to patients. Maintaining 
mobility and walking helps in terms of indepen-
dence, balance and general health. However, falls are 
an inevitable feature of PSP, and can lead to serious 
injury, a premature loss of functional independence, 
and anxiety. We have reviewed the approach to falls 
management in PSP elsewhere.6 While there is no 
strong evidence- based approach to reducing falls risk 
in PSP, we advocate a personalised approach to address 
polypharmacy, nocturia and impulsivity.
Consider bone protection to reduce the risk of frac-
ture. Vitamin D deficiency is very common in the UK, 
and particularly so among people with PSP. Commu-
nity fracture risk estimates (eg, “FRAX” Fracture Risk 
Assessment Tool scores) do not accommodate the falls 
frequency of PSP. We therefore recommend a low 
threshold for DEXA scanning, and proactive manage-
ment of osteopenia and osteoporosis with Calcium- D3, 
and a bisphosphonate where indicated. The dysphagia 
of PSP increases the risk of severe oesophageal injury 
with oral bisphosphonates, so infusion- based alterna-
tives may be required.
Dysphagia leading to weight loss and aspiration is 
common in PSP. We recommend monitoring weight 
and advising families to come forward if there are 
symptoms of a chest infection. Aspiration may be 
heralded by coughing and choking but may be silent. 
Seek early assessment by SL therapy colleagues, with 
a view to advice on safer eating, timing of modified 
diets and fluid thickeners, and discussions in selected 
patients on feeding alternatives such as percutaneous 
endoscopic gastrostomy (PEG) tube. PEG reduces but 
does not entirely prevent aspiration. Exhaustingly long 
mealtimes, weight loss, reduced resilience to infection 
and pressure sores, and frightening episodes of choking 
may all be ameliorated by PEG feeding. A PEG tube 
does not exclude eating for pleasure: favourite food 
and drink can be a continuing source of enjoyment and 
social engagement, while the PEG handles the bulk 
nutrition. In our clinic, about half of patients accept 
the offer of PEG.
Arguably the most important way to reduce risks is 
to avoid harmful medication. People with PSP can be 
exquisitely sensitive to neuroleptics, with catastrophic 
and irreversible worsening of an extrapyramidal 
syndrome. Psychosis and agitation are rare, although 
can be induced by medications (eg, anticholinergics, 
opiates, amantadine) and infection (chest, urine, even 
without fever). Short courses of short- acting seda-
tives or hypnotics have a role, provided other exacer-
bating factors have been addressed. But avoid typical 
(eg, haloperidol) and most atypical (eg, risperidone) 
neuroleptics. Quetiapine probably carries least risk of 
harm, but with questionable efficacy.
Review other medications and try to reduce well- 
intentioned but unnecessary polypharmacy. For 
example, was the speech problem attributed to a 
small stroke actually the start of the PSP? If so, the 
aspirin and angiotensin converting enzyme inhibitor 
may not be needed. Is there a solid reason for that 
statin? Remember that patients with PSP have survival 
expectation of 3 years from diagnosis, not a 10- year 
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modifiable cardiovascular risk. Focus on treatments 
that are priorities for symptoms and significant health 
risks.
Disease-modifying treatments
Several agents have been tried in completed phase 
II/III clinical trials of Richardson’s syndrome. These 
have been successful in galvanising the international 
PSP community, and demonstrating feasibility of PSP 
trials, with important lessons learnt about trial design 
and end points. They have not shown clinical efficacy. 
However, several clinical trials are underway and in 
preparation for 2021–2022. We look forward to one 
of these demonstrating efficacy to slow progression. 
But there is no need to be passive in the interim, with 
so much else to consider in treating the symptoms that 
trouble the patient.
Non-drug support
The coordination of non- pharmacological manage-
ment is as important as drug management. Support for 
patients and families at different stages of disease will 
require input from a diverse multi- disciplinary team, 
from hospital and community services in health and 
social care. The provision of these services, and profes-
sional boundaries and titles, varies greatly between 
regions. These teams often look to the patient’s 
neurologist for information, recommendations, and 
advice. So, what can you do?
Be liberal with ‘to whom it may concern letters’ as 
these improve access to medical services in the commu-
nity, social services support or even travel insurance to 
enable patients to take a break or meet family abroad. 
Send copies of your clinic letters to patients, so they 
have critical information to hand when meeting other 
doctors or are admitted to hospital elsewhere.
The multidisciplinary team and other professional 
partners in care may include, but are not limited to:
1. General practitioner.
2. Specialist nurses: Parkinson’s disease specialist nurse, 
neurology specialist nurse, dementia specialist nurses.
3. District nurse, and community matron.
4. Palliative care team, hospice and home support.
5. Physiotherapist: ideally neurophysiotherapy specialist 
team.
6. Occupational therapist.
7. Speech and Language therapist.








14. Independent living team.
15. Advisers on financial support, benefits, pensions, 
power of attorney, from third sector organisations (eg, 
Citizens’ Advice Bureau, AgeUK, Alzheimer society, 
PSP Association).
16. Independent adviser on continuing healthcare (eg, 
Beacon Healthcare).
Try to identify a named keyworker to coordinate 
care and help the patient and carer navigate the health 
and social care system, with its Byzantine procedures. 
In direct support of your medical care, the Speech and 
Language therapist is especially important. Almost 
every person with PSP will develop dysphagia sooner 
or later. Early awareness and assessment are critical, 
with practical measures the patient and carer can 
take to reduce the risk of aspiration and, in conjunc-
tion with a dietician, reduce the risk of malnutrition. 
Recurrent aspiration accelerates the course of disease. 
Patients with PSP may be in a catabolic state, which, 
together with slow eating, leads to calorie deficits and 
vitamin deficiency, with weight loss that exacerbates 
fatigue and risks of injury from falls.
Physiotherapists and occupational therapists play 
a key role in PSP care, and in many areas provide a 
coordinated community- based service. The PSP Asso-
ciation publish ‘A guide to PSP and corticobasal degen-
eration for occupational therapists’, setting out roles 
and activities as educators and network facilitators, 
and as problem solvers for safe independent living. 
Mobility, transfers, falls management, personal care, 
vision, eating, cognitive change, palliation and goal 
setting for rehabilitation: these complex domains of 
PSP can each benefit from physiotherapy and occupa-
tional therapist assessment and support for the patient 
and carers.
Palliative care
The involvement of palliative care teams can be 
hugely beneficial. Such teams often have a wide range 
of services, many not available elsewhere, and more 
readily accessible. These may include psychological 
support or group sessions. The timing of palliative 
care input can be a delicate discussion, but in general 
we advocate early involvement, particularly where 
anxieties about the end of the illness are a major issue. 
The palliative care team may help advanced care plan-
ning, symptom control, family support and day- centre 
activities.
Empowered patients and expert families
PSP is rare. Most of the people your patients meet on 
their pathway through health and social care will not 
have heard of it, let alone seen it. This is a source of 
great frustration, and undermines confidence in the 
services they need. You can help the patient and family 
by building their experience, knowledge and confi-
dence, to become ambassadors and experts in PSP. 
They can be given the confidence to take the lead and 
help those they meet to orientate quickly to PSP.
The PSP Association is a valuable source of infor-
mation—for you, the patient, their family and other 
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professionals. Their website https:// pspassociation. 
org. uk/ and phoneline 0300 0110 122 are a portal for:
1. A group for newly diagnosed people.
2. Local groups, online support and blogs for more experi-
enced patients and carers.
3. Support for children affected by PSP in the family.
4. Information and downloadable leaflets about PSP, in part 
to give to others they meet.
5. Interactive resource for professionals https:// hscpguide. 
com/ and downloadable guidance for general practi-
tioners, occupational therapists, physiotherapists, Na-
tional Health Service continuing healthcare funding and 
more.
6. Contact for care- workers supporting people with PSP.
7. Educational days for health and social care professionals.
8. Support for carers
It is sensible for patients and families dealing with 
chronic progressive neurological conditions to set up 
Lasting Powers of Attorney, but this needs to be done 
while the patient has mental capacity. Mental capacity 
for major health and financial decisions is usually 
preserved in PSP, until very late in the illness. Mental 
capacity rests on the ability to:
1. Understand information given: in PSP, use simplified lan-
guage, short direct sentences, and in a form the person 
can read or hear clearly.
2. Retain that information long enough to be able to make 
the decision: in PSP, this needs an unhurried and non- 
distracting environment.
3. Weigh up the information available to make the decision: 
PSP causes slow thinking and executive impairment. Pa-
tience is needed on your part. In normal conversations, a 
reply begins within half a second, but in PSP it may take 
10–20 s.
4. Communicate a decision: this can be especially difficult 
but make it your problem not theirs. Speech may be a 
whisper, but that is sufficient. Communicating with a 
thumbs up/down is also usually sufficient to indicate au-
tonomous decision making, however careful we need to 
be to understand the decision. Every effort must be made 
to find ways for the patient to communicate, before com-
munication difficulty is misinterpreted as loss of mental 
capacity.
CONCLUSION
Working with patients and families affected by PSP 
provides a great opportunity for active manage-
ment. It begins with early diagnosis, to make sense of 
their experiences including the change in cognition, 
personality and behaviour. This leads on to proac-
tive management of the myriad symptoms of PSP and 
risk mitigation, drawing on basic principles of good 
medical care. It is easy to bamboozle someone with 
PSP—but you can be their champion, to empower 
them through the health and social care system, to 
deal with their priority symptoms and to defend their 
rights and autonomy.
Quick links to further information
Video examination signs: www. sciencedirect. com/ 
science/ article/ pii/ S1353802020302078? via% 3Dihub
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Key points
1. Progressive supranuclear palsy (PSP) is very different 
to Parkinson’s disease with readily distinguishable 
features
2. PSP is a clinical diagnosis; imaging helps to 
differentiate mimics.
3. Non- pharmacological management of PSP is as 
important as pharmacological treatment and should 
be implemented early.
4. Empower patients and their families to make well- 
informed autonomous decisions about their care, and 
aim to preserve their quality of life.
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